Novartis license smoking fix

Novartis said it's agreed to license an anti-smoking vaccine, CYT002-NicQb, from Cytos .

The vaccine is due to begin Phase III trials in 2008.

Cytos said it could get a total of 600 million Swiss francs ($496 million) in milestone payments, including 35 million francs up front, plus royalties on net sales.